ID
45473
Descripción
Principal Investigator: Laura Pasqualucci, MD, Institute for Cancer Genetics, Columbia University, New York, NY, USA MeSH: Lymphoma, Non-Hodgkin,Lymphoma, B-Cell https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000502 Splenic Marginal Zone Lymphoma (SMZL) is a B-cell malignancy of unknown pathogenesis and thus orphan of targeted therapies. By integrating whole-exome sequencing and copy-number analysis of 8 paired tumor-normal DNAs from patients with SMZL, we show that the typical SMZL exome carries ~30 genetic alterations. Targeted resequencing of selected candidates in an extended panel of 40-117 samples revealed activating mutations of NOTCH2, a gene required for marginal-zone (MZ) development, as the most frequent and SMZL-specific lesion, accounting for approximately 20% of cases. Additional altered genes suggest that deregulation of signaling pathways normally involved in MZ development (NOTCH, NF-kappa B, and B-cell receptor) represents a critical event in SMZL pathogenesis. These findings have direct implications for the treatment of SMZL patients since drugs are available which can target NOTCH as well as other pathways deregulated in this disease.
Link
Palabras clave
Versiones (2)
- 31/10/22 31/10/22 - Tabea Kampen
- 13/12/22 13/12/22 - Kristina Keller
Titular de derechos de autor
Laura Pasqualucci, MD, Institute for Cancer Genetics, Columbia University, New York, NY, USA
Subido en
13 de diciembre de 2022
DOI
Para solicitar uno, por favor iniciar sesión.
Licencia
Creative Commons BY 4.0
Comentarios del modelo :
Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.
Comentarios de grupo de elementos para :
Comentarios del elemento para :
Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.
dbGaP phs000502 Genome-Wide Analysis of Splenic Marginal Zone Lymphoma
Eligibility Criteria
- StudyEvent: SEV1
- Eligibility Criteria
- Subject ID and consent group of participants with splenic marginal zone lymphoma and involved in the "Genome-Wide Analysis of Splenic Marginal Zone Lymphoma" project.
- Sample ID, subject ID and sample use variables obtained from participants with splenic marginal zone lymphoma and involved in the "Genome-Wide Analysis of Splenic Marginal Zone Lymphoma" project.
- Sample ID, analyte type, tumor status, body site where sample was collected, and histological diagnosis of tumors obtained from participants with splenic marginal zone lymphoma and involved in the "Genome-Wide Analysis of Splenic Marginal Zone Lymphoma" project.
Similar models
Eligibility Criteria
- StudyEvent: SEV1
- Eligibility Criteria
- Subject ID and consent group of participants with splenic marginal zone lymphoma and involved in the "Genome-Wide Analysis of Splenic Marginal Zone Lymphoma" project.
- Sample ID, subject ID and sample use variables obtained from participants with splenic marginal zone lymphoma and involved in the "Genome-Wide Analysis of Splenic Marginal Zone Lymphoma" project.
- Sample ID, analyte type, tumor status, body site where sample was collected, and histological diagnosis of tumors obtained from participants with splenic marginal zone lymphoma and involved in the "Genome-Wide Analysis of Splenic Marginal Zone Lymphoma" project.
C0332155 (UMLS CUI [1,2])
C1515568 (UMLS CUI [1,3])
C0349632 (UMLS CUI [1,4])
C0150103 (UMLS CUI [1,2])
C0205307 (UMLS CUI [2,1])
C0017428 (UMLS CUI [2,2])
C0012854 (UMLS CUI [2,3])
Sin comentarios